MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy

loannis Kostopoulos; Loannis Ntanasis-Stathopoulos; Nikolaos Aggelis; Panos Malandrakis; Evangelos Eleftherakis-Papaiakovou; Pantelis Rousakis; Chrysanthi Panteli; Nikolaos Kanelias; Despina Fotiou; Magdalini Migkou; Maria Gavriatopoulou; Efstathios Kastritis; Ourania Tsitsilonis; Meletios A Dimopoulos; Evangelos Terpos

doi:10.1016/s2152-2650(22)01626-3

Related publications

Article2022

Poster: MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy

Ioannis V. Kostopoulos, Ioannis Ntanasis‐Stathopoulos, Nikolaos Aggelis, Panos Malandrakis, Evangelos Eleftherakis-Papaiakovou, Pantelis Rousakis, Chrysanthi Panteli, Nikolaos Kanelias, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Ourania Tsitsilonis, Meletios A Dimopoulos, Evangelos Terpos

Article2019

Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy

Ioannis V. Kostopoulos, Efstathios Kastritis, Αριστέα-Μαρία Παπανώτα, Paraskevi Micheli, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios A Dimopoulos, Evangelos Terpos

Article2024

OA-16 Long-Term Evaluation of Minimal Residual Disease Dynamics in Multiple Myeloma Patients Achieving Complete Response After First Line Treatment

Ioannis V. Kostopoulos, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Panagiotis Bakouros, Pantelis Rousakis, Nikolaos Tsakirakis, Evangelos Eleftherakis-Papaiakovou, Nikolaos Angelis, Vasiliki Spiliopoulou, Chrysanthi Panteli, Rodaanthi-Eleni Syrigou, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Article2019

Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy

Panagiotis Malandrakis, Nikolaos Kanellias, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Magdalini Migkou, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Ourania Tsitsilonis, Meletios A Dimopoulos, Evangelos Terpos, Ioannis V. Kostopoulos, Evangelos Eleutherakis‐Papaiakovou, Αριστέα-Μαρία Παπανώτα, Paraskevi Micheli

Article2019

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Evangelos Terpos, Ioannis V. Kostopoulos, Efstathios Kastritis, Ioannis Ntanasis‐Stathopoulos, Magdalini Migkou, Pantelis Rousakis, Alexandra Argyriou, Nikolaos Kanellias, Despina Fotiou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Dimitrios C. Ziogas, Αριστέα-Μαρία Παπανώτα, Marilyn Spyropoulou-Vlachou, Ioannis P. Trougakos, Ourania Tsitsilonis, Bruno Paiva, Meletios A Dimopoulos

MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy

Discussion(0)

Related publications

Poster: MM-468 Longitudinal Assessment of Minimal Residual Disease Dynamics in Patients With Multiple Myeloma who Achieve Complete Response after First Line Therapy

Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy

OA-16 Long-Term Evaluation of Minimal Residual Disease Dynamics in Multiple Myeloma Patients Achieving Complete Response After First Line Treatment

Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy